Elicit: Downstream Pathways of Dulaglutide Effects
Downstream Pathways of Dulaglutide Effects
What downstream pathways explain dulaglutide's effects on glucagon secretion and gastric emptying?
Dulaglutide suppresses glucagon secretion through a paracrine somatostatin pathway mediated by SSTR2 receptors on pancreatic alpha cells, while the specific downstream pathways for gastric emptying delay remain unelucidated beyond GLP-1 receptor activation.
Abstract
Seven studies investigated dulaglutide’s mechanisms, though only three directly examined pathways for glucagon secretion or gastric emptying effects. For glucagon suppression, perfused pancreas experiments demonstrated that GLP-1 operates entirely through a paracrine somatostatin pathway: GLP-1 stimulates somatostatin secretion, which then acts through somatostatin receptor 2 (SSTR2) on pancreatic alpha cells to inhibit glucagon release. Blocking SSTR2 completely eliminated GLP-1’s glucagon-lowering effect, with glucagon secretion increasing by 118.8-162.9%. This inhibitory effect persists across glucose concentrations from 6.0 to 0.5 mmol/l, though how this mechanism avoids suppressing physiologically necessary glucagon responses to hypoglycemia in vivo remains unexplained.
In contrast, evidence for gastric emptying pathways came exclusively from computational models that incorporated gastric emptying delay as a GLP-1 receptor-mediated effect without specifying downstream cellular, neural, or smooth muscle mechanisms. The delay is most pronounced after initial dosing and diminishes with repeated administration, suggesting pharmacological tolerance distinct from the glucagon pathway, where GLP-1 receptor expression is maintained despite chronic exposure. This mechanistic asymmetry likely reflects methodological constraints: isolated perfused organs permit detailed study of paracrine islet signaling, while gastric emptying involves complex neuro-hormonal interactions not readily studied in reductionist experimental systems. Detailed mechanistic investigation of dulaglutide’s gastric emptying effects using ex vivo or in vivo approaches comparable to those applied for glucagon secretion has not been conducted.
Methods
We analyzed 7 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question.
Paper search
We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.
We ran this query: "What downstream pathways explain dulaglutide’s effects on glucagon secretion and gastric emptying?"
The search returned 200 total results from Elicit. We retrieved 200 papers most relevant to the query for screening.
Screening
We screened in sources based on their abstracts that met these criteria:
- Primary Intervention: Does this study investigate dulaglutide as the primary intervention (not just as a comparator or control)?
- Target Outcomes: Does this study measure or investigate glucagon secretion, gastric emptying, or both as outcomes?
- Mechanistic Focus: Does this study examine, measure, or discuss downstream pathways, molecular mechanisms, signaling cascades, or mechanistic explanations?
- Study Design: Is this an experimental study (randomized controlled trial, non-randomized controlled trial, before-after study, or mechanistic study)?
- Study System: Is this study conducted in human subjects, animal models, or in vitro systems?
- Mechanistic Investigation: Does this study include mechanistic investigation beyond solely reporting clinical outcomes?
- Study Type Quality: Is this study something other than a case report, case series, editorial, or opinion piece?
We considered all screening questions together and made a holistic judgement about whether to screen in each paper.
Data extraction
We extracted the following data columns from each paper:
- Study Model: Type of model, specific cell lines or populations, experimental conditions, limitations.
- Target Effects: Effects investigated (glucagon secretion, gastric emptying, etc.) and measurement methods.
- Glucagon Pathways: Downstream pathways and mechanisms explaining dulaglutide’s effects on glucagon secretion.
- Gastric Emptying Pathways: Mechanisms and implications of gastric emptying delay.
- Mechanistic Evidence: Experimental evidence supporting the identified pathways.
- Key Findings: Main conclusions about mechanistic effects of dulaglutide.
- Mechanistic Gaps: Limitations and gaps in understanding its mechanisms.
Results
Characteristics of included studies
Seven studies investigated dulaglutide’s mechanisms; however, only three examined pathways for glucagon secretion or gastric emptying effects.
Summary of Studies:
| Study | Full text retrieved? | Model type | Target effects investigated |
|---|---|---|---|
| Kimura et al. (2018) | No | Animal model: db/db and db/m mice; 0.6 mg/kg twice weekly | GLP-1R expression and insulin secretion |
| Darwish et al. (2023) | No | Animal model: Male C57BL/6 mice | Depression-related pathways via GLP-1R/cAMP/PKA |
| Lee et al. (2022) | Yes | In vitro: HepG2 cells | Hepatic lipid metabolism via FAM3A pathway |
| El Mahdy et al. (2024) | Yes | Animal model: Male Sprague-Dawley rats | Ulcerative colitis via TGF-β/PI3K/NF-κB pathways |
| Ørgaard & Holst (2017) | Yes | Perfused mouse pancreas | Glucagon secretion inhibition |
| Posada et al. (2025) | Yes | Computational modeling | Gastric emptying delay effects on drug absorption |
| Bosch et al. (2021) | Yes | Computational QSP model | Glucose regulation including glucagon modulation |
Downstream pathways for glucagon secretion
The most direct mechanistic evidence came from a perfused mouse pancreas study demonstrating that GLP-1 inhibited glucagon secretion significantly when acting through a somatostatin pathway.
Downstream pathways for gastric emptying
Evidence for gastric emptying effects came mostly from computational models that evaluated pharmacological responses that lead to delayed gastric emptying primarily mediated by GLP-1 receptors.
Studies investigating alternative pathways
Four studies examined dulaglutide’s effects on other physiological systems through various molecular pathways, although these did not directly address glucagon secretion or gastric emptying mechanisms.
Synthesis
The evidence shows a gap in understanding glucagon suppression mechanisms versus gastric emptying delay. Experimental studies reveal a paracrine pathway for glucagon secretion while gastric emptying mechanisms require further investigation to elucidate intricate interactions.
References
- Posada et al., 2025.
- Kimura et al., 2018.
- Lee et al., 2022.
- El Mahdy et al., 2024.
- Darwish et al., 2023.
- Ørgaard & Holst, 2017.
- Bosch et al., 2021.